| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Integrated genomic characterization of endometrial carcinoma.
|
Nature
|
2013
|
14.29
|
|
2
|
Absolute quantification of somatic DNA alterations in human cancer.
|
Nat Biotechnol
|
2012
|
10.87
|
|
3
|
Resistance to therapy caused by intragenic deletion in BRCA2.
|
Nature
|
2008
|
5.85
|
|
4
|
Rethinking ovarian cancer: recommendations for improving outcomes.
|
Nat Rev Cancer
|
2011
|
5.28
|
|
5
|
Common variants at 19p13 are associated with susceptibility to ovarian cancer.
|
Nat Genet
|
2010
|
4.51
|
|
6
|
Evaluating cell lines as tumour models by comparison of genomic profiles.
|
Nat Commun
|
2013
|
4.35
|
|
7
|
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.
|
Nat Genet
|
2013
|
4.35
|
|
8
|
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer.
|
Cancer Res
|
2008
|
4.05
|
|
9
|
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.
|
JAMA
|
2012
|
3.85
|
|
10
|
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
|
J Clin Invest
|
2012
|
3.64
|
|
11
|
Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.
|
J Clin Oncol
|
2010
|
3.54
|
|
12
|
Genomic and biological characterization of exon 4 KRAS mutations in human cancer.
|
Cancer Res
|
2010
|
3.24
|
|
13
|
Inferring tumour purity and stromal and immune cell admixture from expression data.
|
Nat Commun
|
2013
|
2.94
|
|
14
|
Gene expression signature with independent prognostic significance in epithelial ovarian cancer.
|
J Clin Oncol
|
2004
|
2.91
|
|
15
|
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
|
Gynecol Oncol
|
2011
|
2.89
|
|
16
|
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers.
|
Sci Transl Med
|
2013
|
2.58
|
|
17
|
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.
|
Gynecol Oncol
|
2009
|
2.45
|
|
18
|
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
|
Ann Surg Oncol
|
2007
|
2.19
|
|
19
|
The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease.
|
Gynecol Oncol
|
2008
|
2.14
|
|
20
|
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
|
Clin Cancer Res
|
2011
|
2.09
|
|
21
|
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.
|
J Natl Cancer Inst
|
2012
|
2.09
|
|
22
|
Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma.
|
PLoS One
|
2012
|
1.76
|
|
23
|
Fertility-sparing radical abdominal trachelectomy for cervical carcinoma: technique and review of the literature.
|
Gynecol Oncol
|
2006
|
1.73
|
|
24
|
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.
|
Nat Commun
|
2013
|
1.73
|
|
25
|
Unique gene expression profile based on pathologic response in epithelial ovarian cancer.
|
J Clin Oncol
|
2005
|
1.64
|
|
26
|
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
|
Gynecol Oncol
|
2006
|
1.64
|
|
27
|
Molecular profiling of endometrial cancers from African-American and Caucasian women.
|
Gynecol Oncol
|
2005
|
1.62
|
|
28
|
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
|
Gynecol Oncol
|
2013
|
1.61
|
|
29
|
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
|
Gynecol Oncol
|
2004
|
1.60
|
|
30
|
Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations.
|
Clin Cancer Res
|
2013
|
1.54
|
|
31
|
Genomic complexity and AKT dependence in serous ovarian cancer.
|
Cancer Discov
|
2012
|
1.50
|
|
32
|
The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas.
|
Gynecol Oncol
|
2010
|
1.37
|
|
33
|
Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.37
|
|
34
|
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
|
J Clin Oncol
|
2008
|
1.36
|
|
35
|
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
|
Nat Commun
|
2013
|
1.36
|
|
36
|
Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?
|
Gynecol Oncol
|
2009
|
1.35
|
|
37
|
Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer.
|
Cancer
|
2009
|
1.32
|
|
38
|
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
|
Cancer
|
2011
|
1.32
|
|
39
|
Genetic analysis of the early natural history of epithelial ovarian carcinoma.
|
PLoS One
|
2010
|
1.25
|
|
40
|
Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer.
|
PLoS One
|
2011
|
1.25
|
|
41
|
Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
|
PLoS One
|
2012
|
1.23
|
|
42
|
A microRNA survival signature (MiSS) for advanced ovarian cancer.
|
Gynecol Oncol
|
2011
|
1.18
|
|
43
|
Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma.
|
J Clin Oncol
|
2006
|
1.18
|
|
44
|
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
|
Clin Cancer Res
|
2009
|
1.16
|
|
45
|
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.
|
Mod Pathol
|
2011
|
1.15
|
|
46
|
A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
|
Gynecol Oncol
|
2009
|
1.14
|
|
47
|
The 6q22.33 locus and breast cancer susceptibility.
|
Cancer Epidemiol Biomarkers Prev
|
2009
|
1.13
|
|
48
|
A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.
|
Cancer
|
2010
|
1.12
|
|
49
|
Time to recurrence and survival in serous ovarian tumors predicted from integrated genomic profiles.
|
PLoS One
|
2011
|
1.09
|
|
50
|
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers.
|
Am J Obstet Gynecol
|
2005
|
1.06
|
|
51
|
Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed?
|
Gynecol Oncol
|
2009
|
1.05
|
|
52
|
Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC).
|
Int J Gynecol Cancer
|
2013
|
1.04
|
|
53
|
Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
|
Gynecol Oncol
|
2011
|
1.04
|
|
54
|
The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women.
|
PLoS One
|
2011
|
1.03
|
|
55
|
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
|
Clin Cancer Res
|
2010
|
1.02
|
|
56
|
Cancer-related infertility in survivorship.
|
Int J Gynecol Cancer
|
2010
|
1.01
|
|
57
|
Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
|
Hum Genet
|
2013
|
0.99
|
|
58
|
A differentiation-based microRNA signature identifies leiomyosarcoma as a mesenchymal stem cell-related malignancy.
|
Am J Pathol
|
2010
|
0.97
|
|
59
|
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.
|
Gynecol Oncol
|
2009
|
0.95
|
|
60
|
A prospective randomized trial comparing patient-controlled epidural analgesia to patient-controlled intravenous analgesia on postoperative pain control and recovery after major open gynecologic cancer surgery.
|
Gynecol Oncol
|
2009
|
0.95
|
|
61
|
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
|
Int J Gynecol Pathol
|
2012
|
0.95
|
|
62
|
Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy.
|
Gynecol Oncol
|
2007
|
0.94
|
|
63
|
Validated gene targets associated with curatively treated advanced serous ovarian carcinoma.
|
Gynecol Oncol
|
2012
|
0.93
|
|
64
|
Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.92
|
|
65
|
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas.
|
Am J Surg Pathol
|
2013
|
0.92
|
|
66
|
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.
|
Cancer Res
|
2013
|
0.89
|
|
67
|
IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
|
Endocr Relat Cancer
|
2007
|
0.89
|
|
68
|
Pediatric radical abdominal trachelectomy for cervical clear cell carcinoma: a novel surgical approach.
|
Gynecol Oncol
|
2005
|
0.88
|
|
69
|
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
|
Int J Gynecol Pathol
|
2016
|
0.88
|
|
70
|
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
|
Gynecol Oncol
|
2009
|
0.87
|
|
71
|
The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
|
Cancer
|
2005
|
0.87
|
|
72
|
Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer.
|
Gynecol Oncol
|
2011
|
0.87
|
|
73
|
Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer.
|
Gynecol Oncol
|
2006
|
0.86
|
|
74
|
Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
|
Gynecol Oncol
|
2012
|
0.86
|
|
75
|
Complex atypical hyperplasia of the uterus: characteristics and prediction of underlying carcinoma risk.
|
Am J Obstet Gynecol
|
2010
|
0.86
|
|
76
|
Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced ovarian, tubal, and peritoneal carcinoma reported to have undergone primary surgical cytoreduction to residual disease 1 cm or less.
|
J Clin Oncol
|
2007
|
0.86
|
|
77
|
Introduction of a computer-based surgical platform in the surgical care of patients with newly diagnosed uterine cancer: outcomes and impact on approach.
|
Gynecol Oncol
|
2012
|
0.85
|
|
78
|
Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study.
|
Radiology
|
2014
|
0.84
|
|
79
|
Analysis of N-glycoproteins using genomic N-glycosite prediction.
|
J Proteome Res
|
2013
|
0.84
|
|
80
|
Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes.
|
J Proteome Res
|
2014
|
0.83
|
|
81
|
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
|
Cancer Immunol Res
|
2014
|
0.82
|
|
82
|
Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.
|
Gynecol Oncol
|
2013
|
0.82
|
|
83
|
Two Distinct Categories of Focal Deletions in Cancer Genomes.
|
PLoS One
|
2013
|
0.82
|
|
84
|
Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
|
Am J Obstet Gynecol
|
2008
|
0.81
|
|
85
|
Low risk of complications associated with the fenestrated peritoneal catheter used for intraperitoneal chemotherapy in ovarian cancer.
|
Gynecol Oncol
|
2008
|
0.81
|
|
86
|
Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1β.
|
Int J Gynecol Pathol
|
2015
|
0.79
|
|
87
|
Exosomal microRNAs step into the biomarker arena.
|
Gynecol Oncol
|
2008
|
0.79
|
|
88
|
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for uterine or cervical cancers.
|
Gynecol Oncol
|
2010
|
0.78
|
|
89
|
The Genomic Heterogeneity of FIGO Grade 3 Endometrioid Carcinoma Impacts Diagnostic Accuracy and Reproducibility.
|
Int J Gynecol Pathol
|
2016
|
0.78
|
|
90
|
Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
|
Am J Surg Pathol
|
2012
|
0.78
|
|
91
|
Postoperative intra-abdominal collections using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier at the time of laparotomy for ovarian, fallopian tube, or primary peritoneal cancers.
|
Gynecol Oncol
|
2009
|
0.78
|
|
92
|
Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
|
Methods Mol Biol
|
2013
|
0.77
|
|
93
|
Intraoperative hypothermia during primary surgical cytoreduction for advanced ovarian cancer: risk factors and associations with postoperative morbidity.
|
Gynecol Oncol
|
2013
|
0.77
|
|
94
|
Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk.
|
Mol Nutr Food Res
|
2014
|
0.77
|
|
95
|
Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes.
|
Am J Surg Pathol
|
2016
|
0.77
|
|
96
|
Prognostic significance of supradiaphragmatic lymphadenopathy identified on preoperative computed tomography scan in patients undergoing primary cytoreduction for advanced epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2010
|
0.77
|
|
97
|
Prognostic factors for patients with stage IV epithelial ovarian cancer receiving intraperitoneal chemotherapy after second-look assessment: results of long-term follow-up.
|
Cancer
|
2008
|
0.76
|
|
98
|
The evolving pathogenesis model of high-grade pelvic serous carcinoma.
|
Gynecol Oncol
|
2011
|
0.75
|
|
99
|
Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer.
|
Nat Genet
|
2015
|
0.75
|
|
100
|
Intra-thoracic cytoreduction of stage IV peritoneal malignancy: a case series.
|
Gynecol Oncol
|
2008
|
0.75
|
|
101
|
44th Annual Meeting of the American Society of Clinical Oncology.
|
Gynecol Oncol
|
2008
|
0.75
|
|
102
|
Gynecologic cancer genomics in the modern era.
|
Gynecol Oncol
|
2013
|
0.75
|
|
103
|
Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation.
|
Gynecol Oncol
|
2004
|
0.75
|
|
104
|
Transcript expression in endometrial cancers from Black and White patients.
|
Gynecol Oncol
|
2013
|
0.75
|
|
105
|
Pathologic analysis of ex vivo plasma energy tumor destruction in patients with ovarian or peritoneal cancer.
|
Int J Gynecol Cancer
|
2010
|
0.75
|